Medibact GuidesShop at Medibact

Stacking Module

Cagrilintide Stacking Module

Cagrilintide is the one compound in this catalog whose main combination has real trial evidence: CagriSema, with semaglutide, is in formal clinical development. That makes it a useful reference point for what a genuinely evidenced combination looks like — and how little else here resembles one.

Cagrilintide Guide at MedibactCagrilintide calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking Cagrilintide

  • Cagrilintide is a long-acting amylin-receptor agonist. Amylin signaling is distinct from incretin signaling, which is the mechanistic basis for combining it with GLP-1 agonists rather than duplicating them.
  • Its half-life is roughly 7-8 days, supporting once-weekly administration and matching semaglutide's schedule — part of why the pairing is practical as a single product.
  • It is investigational as a standalone; CagriSema is under regulatory review rather than approved.
  • This is the only combination in the catalog with controlled human data, and that data exists because it was developed as a product, not assembled by users.

Combinations in detail

CagriSema (clinical combination)

Cagrilintide + Semaglutide
Why it is proposed
Amylin and GLP-1 pathways are reported to act additively on appetite. Phase 3 data reported substantially greater weight reduction than semaglutide alone — genuine combination evidence, which is rare here.
What is reported in practice
In trials both are once weekly with independent titration, developed as a single fixed combination product.
Cautions specific to this combination
The evidence attaches to the studied product under trial monitoring, not to two research-market vials combined at home. Semaglutide's boxed warning and contraindications apply regardless.

Amylin + dual incretin (reported)

Cagrilintide + Tirzepatide
Why it is proposed
Amylin agonism alongside a dual GIP/GLP-1 agonist — mechanistically non-overlapping.
What is reported in practice
Community-reported; the studied amylin pairing is with semaglutide.
Cautions specific to this combination
No trial data for this configuration. Gastrointestinal effects compound across both.

Next-gen incretin pairing (reported)

Cagrilintide + Retatrutide
Why it is proposed
Amylin plus triple incretin agonism; non-overlapping on receptors.
What is reported in practice
Community-reported only.
Cautions specific to this combination
Both investigational, no approved label between them, no combination data.

What to avoid, and why

  • Treating a self-assembled cagrilintide-plus-semaglutide combination as equivalent to CagriSema — the trial evidence covers a developed product administered under monitoring.
  • Combining it with two incretin agonists at once; the gastrointestinal burden is additive and none of it has been studied.
  • Assuming its trial titration schedule transfers to a different partner compound.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.